[go: up one dir, main page]

SG11201809652PA - Treatment of skin lesions - Google Patents

Treatment of skin lesions

Info

Publication number
SG11201809652PA
SG11201809652PA SG11201809652PA SG11201809652PA SG11201809652PA SG 11201809652P A SG11201809652P A SG 11201809652PA SG 11201809652P A SG11201809652P A SG 11201809652PA SG 11201809652P A SG11201809652P A SG 11201809652PA SG 11201809652P A SG11201809652P A SG 11201809652PA
Authority
SG
Singapore
Prior art keywords
international
formula
independently
optionally substituted
basel
Prior art date
Application number
SG11201809652PA
Inventor
Doriano Fabbro
Paul Hebeisen
Petra Hillmann-Wuellner
Anton Stuetz
John Seykora
Florent Beaufils
Original Assignee
Piqur Therapeutics Ag
The Trustees Of The Univ Of Pennesylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piqur Therapeutics Ag, The Trustees Of The Univ Of Pennesylvania filed Critical Piqur Therapeutics Ag
Publication of SG11201809652PA publication Critical patent/SG11201809652PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 DOI 010111110101111 0 111 Oil Mil 11111001101111111110 lil Oil lil Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\"1 WO 2017/198347 Al 23 November 2017 (23.11.2017) WIPO I PCT (51) International Patent Classification: trasse 49b, 8102 Oberengstringen (CH). STUETZ, Anton; A61K 31/00 (2006.01) A61K 31/5386 (2006.01) Teichweg 4, 4813 Altmiinster (CH). SEYKORA, John, T.; A61K 31/5377 (2006.01) A61P 17/02 (2006.01) 202 Laurel Lane, Broomall, PA 19008 (US). BEAUFILS, (21) International Application Number: Florent; 28 rue des ecureuils, 68870 Bartenheim (FR). PCT/EP2017/025137 (74) Agent: SPERRLE, Martin; Austrasse 24, 4051 Basel (22) International Filing Date: (CH). 17 May 2017 (17.05.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/338,111 18 May 2016 (18.05.2016) US HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, 17151843.4 17 January 2017 (17.01.2017) EP KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (71) Applicants: PIQUR THERAPEUTICS AG [CH/CH]; PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, Hochbergerstrasse 60c, 4057 Basel (CH). THE TRUS- SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TEES OF THE UNIVERSITY OF PENNESYLVANIA TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. _ [US/US]; 3160 Chestnut Street, Suite 200, Philadelphia, PA (84) Designated States (unless otherwise indicated, for every 19104 (US). kind of regional protection available): ARIPO (BW, GH, (72) Inventors: FABBRO, Doriano; Im Lee 54, 4144 Ar- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, leshiem (CH). HEBEISEN, Paul; St. Albanring 184, 4052 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Basel (CH). HILLMANN-WUELLNER, Petra; Dorfs- TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = = Title: TREATMENT OF SKIN LESIONS (54) = R 2 1. 1 , 2F . ,. , R ,,), ,4 W F 0 R3_ R4 x';'\"\" , ...,.... . , N > _ = ,..i, (II) ' :::: N N H 2 = — (I) = = A A = = = : The present invention is relates to a compound of formula (I), wherein X 1 , X 2 and X 3 are, independently of each other, N (57) CH; with the proviso that at least two of X 1 X 2 and X are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X 3 1 , X 2 X 3 are N; R 1 and R 2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula or — and - (I); and wherein R 3 and R are independently of each other H, C 4 1 -C 3 alkyl optionally substituted with one or two OH, C 1 -C 2 fluoroalkyl, Ci -C2alkoxy, ClalkoxyCj-C3alkyl, CN, or C(0)0-Ci-C2alkyl; or R 3 and R 4 form together a bivalent residue -R 5 R 6 - selected from C1- Ir -- - iv C3alkylene optionally substituted with 1 to 4 F, -CH2-0-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the M bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally GC c:N substituted by 1 to 3 R 7 ; wherein R 7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1- C2fluoroalkyl, --.... Ci-C2alkoxyCj-C3alkyl, C3-C6cycloalkyl; or two R 7 substituents form together a bivalent residue-R R - selected from 8 9 IN p is Il Ci-C3alkylene optionally substituted with 1 to 4 F, -CH2-0-CH2- or -O-CH2CH2-O-; with the proviso that at least one of R 1 and © a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in el the prevention or treatment of a skin lesion in a subject. [Continued on next page] WO 2017/198347 Al MIDEDIMOMOIDEIROIDEMOMMUNDOMOHMEMIDIMIE EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply patent (Rule 4.17(H)) for and be granted a Published: — with international search report (Art. 21(3))
SG11201809652PA 2016-05-18 2017-05-17 Treatment of skin lesions SG11201809652PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338111P 2016-05-18 2016-05-18
EP17151843 2017-01-17
PCT/EP2017/025137 WO2017198347A1 (en) 2016-05-18 2017-05-17 Treatment of skin lesions

Publications (1)

Publication Number Publication Date
SG11201809652PA true SG11201809652PA (en) 2018-12-28

Family

ID=57850922

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809652PA SG11201809652PA (en) 2016-05-18 2017-05-17 Treatment of skin lesions

Country Status (6)

Country Link
EP (1) EP3458035A1 (en)
AU (1) AU2017265384B2 (en)
CA (1) CA3022758C (en)
SG (1) SG11201809652PA (en)
TW (1) TWI780049B (en)
WO (1) WO2017198347A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3458067T (en) 2016-05-18 2021-04-07 Univ Basel Treatment of neurological disorders
WO2019101853A1 (en) 2017-11-23 2019-05-31 Piqur Therapeutics Ag Treatment of skin disorders
WO2025125469A1 (en) 2023-12-13 2025-06-19 Swiss Rockets Ag Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor
WO2025181366A1 (en) 2024-03-01 2025-09-04 Torqur Ag Topical formulations of dual pi3k/mtor inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2012099968A1 (en) * 2011-01-19 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating skin cancer associated diseases
BR112013020159A2 (en) * 2011-02-11 2016-11-08 Dana Farber Cancer Inst Inc method to inhibit hamartoma tumor cells
US9296733B2 (en) * 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CN104245693B (en) * 2012-12-14 2016-08-24 上海恒瑞医药有限公司 Pyrimidine derivatives and their pharmaceutically acceptable salts, their preparation methods and their applications in medicine
US20150065431A1 (en) * 2013-08-27 2015-03-05 Northwestern University Reducing cutaneous scar formation and treating skin conditions
CN103483345B (en) * 2013-09-25 2016-07-06 中山大学 PI3K inhibitors of kinases, the pharmaceutical composition comprising it and application thereof
CN104557871B (en) * 2013-10-28 2017-05-03 上海汇伦生命科技有限公司 Arylmorpholine compounds with spiro substituents as well as preparation method and use thereof
MA40933A (en) * 2014-11-11 2017-09-19 Piqur Therapeutics Ag DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES

Also Published As

Publication number Publication date
WO2017198347A1 (en) 2017-11-23
CA3022758C (en) 2024-02-06
TWI780049B (en) 2022-10-11
AU2017265384B2 (en) 2023-02-23
WO2017198347A8 (en) 2025-06-19
AU2017265384A1 (en) 2018-12-20
EP3458035A1 (en) 2019-03-27
TW201808943A (en) 2018-03-16
CA3022758A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201804934PA (en) Novel Compounds
SG11201908670SA (en) Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
SG11201902938TA (en) Compounds, devices, and uses thereof
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201808907PA (en) Inhibitors of activin receptor-like kinase
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201806745RA (en) Sulfonylureas and related compounds and use of same
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201808990QA (en) Compositions for topical application of compounds
SG11201811074RA (en) Nant cancer vaccine
SG11201809342YA (en) Pyrimidine compounds as jak kinase inhibitors
SG11201907023UA (en) Method of reducing neutropenia
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11201906222WA (en) Jak1 selective inhibitors
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201811686UA (en) 18f-labeled triazole containing psma inhibitors
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201903326RA (en) Liposomal formulation for use in the treatment of cancer